.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,994,364

« Back to Dashboard
Patent 7,994,364 protects NUCYNTA and NUCYNTA ER and is included in three NDAs. There have been zero Paragraph IV challenges on Nucynta and Nucynta ER

This patent has twenty-nine patent family members in twenty-four countries.

Summary for Patent: 7,994,364

Title:Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Abstract: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
Inventor(s): Fischer; Andreas (Huertgenwald, DE), Buschmann; Helmut (Esplugues de Llobregat, ES), Gruss; Michael (Aachen, DE), Lischke; Dagmar (Eschweiler, DE)
Assignee: Gruenenthal GmbH (Aachen, DE)
Application Number:12/634,777
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 4th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-001Nov 20, 2008RXNo7,994,364► subscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-002Nov 20, 2008RXNo7,994,364► subscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
Depomed Inc
NUCYNTA
tapentadol hydrochloride
TABLET;ORAL022304-003Nov 20, 2008RXYes7,994,364► subscribeYY RELIEF OF MODERATE TO SEVERE ACUTE PAIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,994,364

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04015091Jun 28, 2004

International Patent Family for Patent: 7,994,364

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1799633► subscribe
Slovenia1612203► subscribe
Russian Federation2423345► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc